MDPI Contact

MDPI AG
St. Alban-Anlage 66,
4052 Basel, Switzerland
Support contact
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18

For more contact information, see here.

Advanced Search

You can use * to search for partial matches.

Search Results

1 article matched your search query. Search Parameters:
Authors = Virgilia Macias

Matches by word:

VIRGILIA (1) , MACIAS (45)

View options
order results:
result details:
results per page:
Articles per page View Sort by
Displaying article 1-50 on page 1 of 1.
Export citation of selected articles as:
Open AccessArticle Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma
Biomolecules 2015, 5(4), 3438-3447; doi:10.3390/biom5043438
Received: 20 August 2015 / Revised: 2 November 2015 / Accepted: 30 November 2015 / Published: 3 December 2015
Cited by 1 | Viewed by 952 | PDF Full-text (5214 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Fallopian adenocarcinoma is a rare malignancy arising in the epithelium of the fallopian tube. Fallopian tube epithelium has been proposed as a tissue origin for high-grade serous ovarian carcinoma, the deadliest gynecologic malignancy. Given the commonalities in dissemination and treatment of these malignancies,
[...] Read more.
Fallopian adenocarcinoma is a rare malignancy arising in the epithelium of the fallopian tube. Fallopian tube epithelium has been proposed as a tissue origin for high-grade serous ovarian carcinoma, the deadliest gynecologic malignancy. Given the commonalities in dissemination and treatment of these malignancies, we contemplated the possibility of similar patterns of gene expression underlying their progression. To reveal potential similarities or differences in the gene expression of fallopian adenocarcinoma and high-grade serous ovarian carcinoma, we tested expression of the fractalkine receptor (CX3CR1) and its ligand, fractalkine (CX3CL1), in the specimens of normal and pathologic fallopian tube using immunohistochemistry. Our data show that CX3CR1 is expressed in the normal, cancer adjacent normal, inflammatory, and malignant fallopian epithelium. CX3CL1 was expressed only by the normal and cancer adjacent normal fallopian tube epithelium; its expression was largely lost in the inflammatory and malignant fallopian epithelium. In opposite, both CX3CR1 and CX3CL1 are expressed in high-grade serous ovarian carcinoma. These findings are consistent with an idea that fallopian adenocarcinoma and high-grade serous ovarian carcinoma, although currently thought to arise from the same organ, may not share similar molecular characteristics. Full article
(This article belongs to the Special Issue Signal Transduction Pathways in Gynecologic Malignancies)

Years

Subjects

Refine Subjects

Journals

Refine Journals

Article Types

Refine Types

Countries

Refine Countries
Back to Top